Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Multicentre Trial of Gemcitabine, CVP, and Rituximab (R-GCVP) for the Treatment of Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma, Considered Unsuitable for R-CHOP Chemotherapy

NCT00971763 is registered in ClinicalTrials.gov with University College, London as lead sponsor.

NCT NCT00971763
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00971763 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Multicentre Trial of Gemcitabine, CVP, and Rituximab (R-GCVP) for the Treatment of Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma, Considered Unsuitable for R-CHOP Chemotherapy
Lead sponsor
University College, London
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2006
Completion date
July 31, 2011
Enrollment
62 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma